SPERIMENTAZIONI NUOVI FARMACI

RADIANT-4 (RAD001 In Advanced NeuroendocrineTumors-4) is a phase III, randomized, double-blind study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced neuroendocrine tumor (NET) of gastrointestinal (GI) or lung origin without a history of carcinoid syndrome

NEUROENDOCRINE TUMOURS: EVALUATION OF PREDICTIVE FACTORS OF DISEASE CONTROL AND TREATAMENT RESPONSE IN A LARGE PATIENTS COHORT.

LOTUS TRIAL: STUDIO RANDOMIZZATO DI FASE III SULL'EFFICACIA DELLA TERAPIA LOCOREGIONALE EPATICA MEDIANTE EMBOLIZZAZIONE TRANSARTERIOSA IN ASSOCIAZIONE A TERAPIA MEDICA CON OCTREOTIDE LAR IN PAZIENTI AFFETTI DA NEOPLASIA NEUROENDOCRINA CON METASTASI EPATICHE INOPERABILI.

 

 

 

 

 

 

 

 

 

MATERIALI ALLEGATI

  • Nessun allegato disponibile